Need professional-grade analysis? Visit stockanalysis.com
$231.25M
N/A
N/A
N/A
Voyager Therapeutics Inc (VYGR) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $4.14, up 0.49% from the previous close.
Over the past year, VYGR has traded between a low of $2.73 and a high of $5.33. The stock has gained 17.3% over this period. It is currently 22.3% below its 52-week high.
Voyager Therapeutics Inc has a market capitalization of $231.25M.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Side-by-side comparison against top Healthcare peers.